<DOC>
	<DOCNO>NCT02496715</DOCNO>
	<brief_summary>This pivotal trial examine therapeutic equivalence ( BE ) new generic fixed-dose combination product contain fluticasone propionate 100 mcg / salmeterol 50 mcg ( xinafoate salt ) reference list drug ( RLD ) Advair® Diskus 100/50 adult patient chronic stable asthma define National Asthma Education Prevention Program Expert Panel Report 3 ( NAEPP 3 ) guideline</brief_summary>
	<brief_title>Randomized , Placebo-controlled Study Comparing Efficacy Fluticasone/Salmeterol Combination Advair Asthmatics</brief_title>
	<detailed_description>This pivotal trial examine therapeutic equivalence new generic fixed-dose combination product contain fluticasone propionate 100 mcg / salmeterol 50 mcg ( xinafoate salt ) reference list drug ( RLD ) Advair® Diskus 100/50 adult patient chronic stable asthma define National Asthma Education Prevention Program Expert Panel Report 3 ( NAEPP 3 ) guideline [ 2 ] . To ensure adequate study sensitivity test reference product statistically superior placebo ( p &lt; 0.05 ) regard BE study primary endpoint . A secondary study objective safety tolerability test compound .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Adult male female subject nonchildbearing childbearing potential committed consistent correct use acceptable method birth control Diagnosed asthma , define National Asthma Education Prevention Program ( NAEPP ) ,5 least 6 month prior screen Moderatetosevere asthma prebronchodilator FEV1 &gt; 45 % &lt; 85 % predict normal , measure least 6 hour shortacting β agonist ( SABA ) least 24 hour last dose longacting β agonist ( LABA ) , screen visit day treatment &gt; 15 % &gt; 0.20 L reversibility FEV1 within 30 minute follow 360 mcg albuterol inhalation ( pMDI ) Patients stable chronic asthma treatment regimen least 4 week prior enrollment Currently nonsmoking ; use tobacco product ( i.e. , cigarette , cigar , pipe tobacco ) within past year , &lt; 10 packyears historical use Able replace current regularly schedule shortacting β agonist ( SABAs ) salbutamol/albuterol inhaler use asneeded basis duration study ( subject able withhold inhale SABAs least 6 hour prior lung function assessment study visit ) Willing discontinue asthma medication ( inhaled corticosteroid longacting β agonist ) runin period remainder study Willingness give write informed consent participate study Lifethreatening asthma , define history asthma episode ( ) require intubation , and/or associate hypercapnia , respiratory arrest hypoxic seizure , asthmarelated syncopal episode ( ) , hospitalization within past year runin period Significant respiratory disease asthma ( chronic obstructive pulmonary disease ( COPD ) , interstitial lung disease , etc . ) Evidence history clinically significant disease abnormality include congestive heart failure , uncontrolled hypertension , uncontrolled coronary artery disease , myocardial infarction , cardiac dysrhythmia . In addition , historical current evidence significant hematologic , hepatic , neurologic , psychiatric , renal , disease , opinion investigator , would put patient risk study participation , would affect study analysis disease exacerbate study Patients require systemic corticosteroid ( reason ) within past 4 week Hypersensitivity sympathomimetic drug ( e.g. , formoterol albuterol ) inhale , intranasal , systemic corticosteroid therapy Patients currently receive βblockers</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>